Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01433094
Other study ID # AIFA FARM892ZXE
Secondary ID
Status Completed
Phase N/A
First received August 20, 2011
Last updated September 6, 2017
Start date September 2012
Est. completion date December 2016

Study information

Verified date September 2017
Source University of Cagliari
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Background: Psychosis in the spectrum of schizophrenia (PSS) are severe mental disorders, with a high impact on disability and participation. Poor adherence to pharmacotherapy negatively impacts on the course and outcome of PSS.

Non-adherence in these patients is 41 to 50%, and it is predictive of a higher risk of relapse and readmission up to 5-time higher than in adherent patients. Falloon et al. developed a Psychoeducation Program (FPP) aimed at improving communication and problem-solving abilities in patients and their families. Past studies reported a statistically significant reduction of the risk of relapse in patients receiving the FPP, but did not take into account effects on adherence.

Objectives: To evaluate changes in adherence to pharmacotherapy in a sample of patients diagnosed with PSS (ICD-10: F20 to F29), by comparing a group exposed to the FPP with another group exposed to a treatment with generic informative prospects on the disorders provided with same attendance frequency as the FPP (Generic Treatment - GT).

Methods: 340 patients with PSS, from 10 participating units distributed in the territory of the Italian National Health System, will be enrolled, with allocation 1:1. The sample will be randomized into an exposed group (to FPP) and an unexposed group. Adherence will be assessed on a three-monthly basis with blood levels of the primary prescribed drug by High Pressure Liquid Chromatography, with a self-report, the Medication Adherence Questionnaire, and concurrently with the administration of a 4-item interview, based on a modified version of the Adherence Interview. Survival analyses will be performed using Kaplan-Meier method, followed by Log-rank test, defining as terminal events both the start of non-adherence and/or the first relapse or readmission episode. Intention-to-treat will be applied in considering the primary and secondary outcomes. Multiple imputations will be applied to integrate missing data.

Expected results: Median prevalence of non-adherence to pharmacotherapy in patients already in contact with a psychiatric service is 47%; effect size of psychosocial treatment on various outcomes, including relapse, readmission and adherence to drug is 0.48 of the standard deviation (SD), with 95% C.I.=0.10 to 0.85. The intervention is expected to produce a change in the prevalence of non-adherence to drug in the exposed group with an effect size of 0.45 SD.


Recruitment information / eligibility

Status Completed
Enrollment 112
Est. completion date December 2016
Est. primary completion date May 2016
Accepts healthy volunteers No
Gender All
Age group 18 Years to 55 Years
Eligibility Inclusion Criteria:

- diagnosis of psychosis in the spectrum of schizophrenia (ICD-10: F20 to F29); -age from 18 to 55;

- being in care for 2 years or more.

Exclusion Criteria:

- mental retardation, or any severe cognitive impairment;

- psychosis due to substance abuse or to a medical condition;

- affective psychosis;

- comorbid substance dependence;

- patient does not understand Italian language;

- pharmacotherapy with depot.

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Falloon et al. Psychoeducation Program
The intervention aims to improve communication and problem-solving abilities in patients and their families by sessions focused on: assessment of the individual's and the family's strengths, weaknesses, and goals; education about schizophrenia and treatment; communication skills training; problem-solving training; and special problems (Falloon et al. 1985). Treatment sessions are provided on a weekly basis for months (1 hour for each session) (groups of about 8-9 persons - patients and caregivers).
Generic Treatment
The comparator is a treatment with generic informative prospect on the disorders and with the same frequencies as the Intervention. Treatment sessions are provided on a weekly basis for 6 months (1 hour for each session) (groups of about 8-9 persons - patients and caregivers).

Locations

Country Name City State
Italy Università Degli Studi Di Bari Bari
Italy Fatebenefratelli Irccs Brescia
Italy Azienda Universitaria Ospedaliera Cagliari Cagliari
Italy Università Degli Studi Di Cagliari Cagliari
Italy Ausl 3 Centro Molise Di Campobasso Campobasso
Italy Università Degli Studi Di Catania Catania
Italy Azienda Ospedaliera Universitaria Policlinico Martino Di Messina Messina
Italy Università Degli Studi Di Urbino "Carlo Bo" Urbino Urbino/Pesaro

Sponsors (1)

Lead Sponsor Collaborator
University of Cagliari

Country where clinical trial is conducted

Italy, 

References & Publications (3)

Falloon IR, Boyd JL, McGill CW, Williamson M, Razani J, Moss HB, Gilderman AM, Simpson GM. Family management in the prevention of morbidity of schizophrenia. Clinical outcome of a two-year longitudinal study. Arch Gen Psychiatry. 1985 Sep;42(9):887-96. — View Citation

Petretto DR, Lussu C, Zuddas C, Pistis I, Piras P, Preti A, et al. Meta-Review of Systematic and Meta-Analytic Reviews on Family Psychoeducation for Schizophrenia. Austin J Clin Neurol 2017; 4(2): 1107.

Petretto DR, Preti A, Zuddas C, Veltro F, Rocchi MB, Sisti D, Martinelli V, Carta MG, Masala C; SPERA-S group. Study on psychoeducation enhancing results of adherence in patients with schizophrenia (SPERA-S): study protocol for a randomized controlled trial. Trials. 2013 Oct 7;14:323. doi: 10.1186/1745-6215-14-323. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Adherence Adherence will be checked with a triple method of assessment: patient's self-report, patient's replies to a four-query interview, and assessment of blood levels of the prescribed drug. Change from baseline in adherence to treatment at 6 months
Secondary Psychotic symptoms The occurrence of psychotic symptoms, according to the Brief psychiatric Rating Scale (BPRS) and the Positive and Negative Syndrome Scale (PANSS) Changes from baseline in levels of psychotic symptoms at 6 months, with effects maintained at12 months and 18 months
Secondary General level of psychopathology The general level of psychopathology will be measured according to the Health of the Nation rating scale (HoNOS) Changes from baseline in levels of general psychopathology at 6 months, with effects maintained at 12 and 18 months
Secondary Changes in the social functioning Social functioning will be measured according to Personal and Social Performance scale (PSP). Quality of life will be measured as well, using the WHO-Quality of Life-Short version (WHOQOL-Bref). Changes from baseline in social functioning at 6 months, maintained at 12 and 18 months
Secondary Readmission An episode of readmission is any admission to a psychiatric service for the necessity of controlling symptoms, behavior or therapy. Admission to the hospital for reason of somatic illness will be not considered an episode of readmission. Occurrence of episodes of readmission over 27 months
See also
  Status Clinical Trial Phase
Completed NCT05083377 - Clozapine Use Pattern in the Province of Seville
Recruiting NCT06313918 - Exercise Therapy in Mental Disorders-study N/A
Recruiting NCT06134661 - Accelerated rTMS for Psychomotor Slowing N/A
Terminated NCT05526833 - An Extension Protocol for Patients Who Previously Completed the TMS Pilot Study N/A
Recruiting NCT05982158 - Avatar-mediated Therapy Versus Cognitive Behavioural Therapy for Persisting Experiences of Hearing Voices N/A
Active, not recruiting NCT06175559 - Embedded Narrative in Interactive Game Design for Improving Medication Adherence of Schizophrenia N/A
Active, not recruiting NCT05673941 - "InMotion" - Physical Training With Creative Movement as an Intervention for Adults With Schizophrenia N/A
Recruiting NCT02916810 - TMS for Symptom Reduction in Schizophrenia N/A
Recruiting NCT05958875 - The Effect of a Six Week Intensified Pharmacological Treatment for Schizophrenia Compared to Treatment as Usual in Subjects Who Had a First-time Treatment Failure on Their First-line Treatment. Phase 4
Recruiting NCT03525054 - Semantic and Syntactic Computerized Analysis of Free Speech
Recruiting NCT05389345 - tDCS and Executive Function Training for Schizophrenia N/A
Completed NCT05601050 - Linguistic Predictors of Outcomes in Psychosis
Completed NCT03075202 - Role of an E-cigarette on Smoking Displacement in Smokers With Schizophrenia
Completed NCT03921450 - Overcoming Psychomotor Slowing in Psychosis (OCoPS-P) N/A
Completed NCT06231407 - Increasing Medication Check Participation Through Applying CT-r N/A
Recruiting NCT04478838 - "Extended" (Alternate Day) Antipsychotic Dosing Phase 4
Completed NCT04366401 - Efficacy of Prebiotic and Probiotic Dietary Modulation in Schizophrenic Disorders N/A
Completed NCT04612777 - A Trial of "Opening Doors to Recovery" for Persons With Serious Mental Illnesses N/A
Not yet recruiting NCT06191965 - MitoQ for Early-phase Schizophrenia-spectrum Disorder and Mitochondrial Dysfunction Phase 2/Phase 3
Recruiting NCT04631939 - Metacognitive Training as a Serious Game N/A